Northern Trust Corp reduced its position in Mednax, Inc (NYSE:MD) by 1.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 972,826 shares of the company’s stock after selling 19,332 shares during the period. Northern Trust Corp owned 1.04% of Mednax worth $58,729,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. boosted its holdings in shares of Mednax by 3.2% in the 1st quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock valued at $125,000 after buying an additional 55 shares in the last quarter. Commonwealth Bank of Australia boosted its holdings in shares of Mednax by 15.3% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock valued at $132,000 after buying an additional 293 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of Mednax by 20.0% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock valued at $181,000 after buying an additional 500 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of Mednax in the 2nd quarter valued at about $217,000. Finally, State of Alaska Department of Revenue boosted its holdings in shares of Mednax by 6.2% in the 2nd quarter. State of Alaska Department of Revenue now owns 4,393 shares of the company’s stock valued at $265,000 after buying an additional 257 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “Mednax, Inc (MD) Stake Decreased by Northern Trust Corp” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/05/mednax-inc-md-stake-decreased-by-northern-trust-corp.html.

MD has been the topic of a number of recent analyst reports. BidaskClub cut shares of Mednax from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Robert W. Baird restated a “hold” rating and issued a $47.00 price target on shares of Mednax in a report on Sunday, September 3rd. Jefferies Group LLC set a $46.00 price target on shares of Mednax and gave the company a “hold” rating in a report on Sunday, July 30th. Mizuho restated a “neutral” rating and issued a $48.00 price target (down from $62.00) on shares of Mednax in a report on Tuesday, August 1st. Finally, KeyCorp upgraded shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 price target on the stock in a report on Sunday, September 17th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $56.63.

Shares of Mednax, Inc (NYSE:MD) opened at 43.66 on Thursday. The firm has a market capitalization of $4.02 billion, a PE ratio of 13.90 and a beta of 0.37. The company has a 50-day moving average of $43.03 and a 200-day moving average of $54.33. Mednax, Inc has a 1-year low of $40.78 and a 1-year high of $72.13.

Mednax (NYSE:MD) last announced its quarterly earnings results on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.04. The firm had revenue of $843.00 million during the quarter, compared to the consensus estimate of $849.49 million. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.03 earnings per share. Equities research analysts predict that Mednax, Inc will post $3.31 EPS for the current fiscal year.

In related news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.40% of the company’s stock.

Mednax Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.